Superluminal — Valuation, Funding & Investors

Recent changes

Sep 3, 2026Sep 3, 2026Raised $60M Series B BioPharma Dive
Sep 3, 2026Sep 3, 2026Superluminal Raises $60M for AI-Designed Obesity Pill Pulse story

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Sep 3, 2026	Series B	$60M	—		Pulse story

Latest Pulse

Sep 3, 2026Superluminal Raises $60M for AI-Designed Obesity PillThe Boston biotech's Series B, backed by Nvidia and Eli Lilly among others, funds Phase 1 trials of an oral MC4R agonist for rare genetic obesity designed by its de novo drug-discovery AI platform.→

Coverage Timeline

newest first

Sep 3, 2026FUNDINGSuperluminal Raises $60M for AI-Designed Obesity Pill$60M Series B→

All Coverage

FUNDING· Sep 3, 2026

Superluminal Raises $60M for AI-Designed Obesity Pill

FUNDING$60M Series B

Superluminal Raises $60M for AI-Designed Obesity Pill

The Boston biotech's Series B, backed by Nvidia and Eli Lilly among others, funds Phase 1 trials of an oral MC4R agonist for rare genetic obesity designed by its de novo drug-discovery AI platform.

Sep 3, 2026DEEP DIVE

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

BioPharma DiveValue Add VC data1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction